Search. Learn. Save

Platform for Pharmaceutical Products for Healthcare Professionals
Search By
☰ Generic Formulas

Generic Formulas X

Aztreonam

Aztreonam: A Comprehensive Overview

Introduction

Aztreonam is a monobactam antibiotic that is used to treat various bacterial infections, particularly those caused by gram-negative bacteria. As a member of the beta-lactam class of antibiotics, Aztreonam shares similar structural features with other beta-lactams but has a unique mechanism of action, spectrum of activity, and clinical applications. It is often prescribed for respiratory, urinary tract, and abdominal infections, as well as infections in immunocompromised patients.

Aztreonam:

Aztreonam is a synthetic monocyclic beta-lactam antibiotic, first developed in the 1980s. Unlike most beta-lactams, which are broad-spectrum and act against both gram-positive and gram-negative bacteria, Aztreonam is narrow-spectrum and is primarily effective against gram-negative bacteria. This specificity makes it an excellent choice for treating infections caused by aerobic gram-negative pathogens like Pseudomonas aeruginosa, Escherichia coli, and Klebsiella pneumoniae. Aztreonam works by inhibiting the bacterial cell wall synthesis, a process that is essential for bacterial survival. It is usually administered intravenously (IV) or intramuscularly (IM), though formulations for inhalation are also available for specific respiratory infections.

Brand Names and Forms

  • Brand Names: Azactam, Cayston.

  • Forms: Aztreonam is available as an intravenous (IV) injection, intramuscular (IM) injection, and inhalation solution.

Mechanism of Action

Aztreonam exerts its antimicrobial effects by binding to and inhibiting bacterial penicillin-binding proteins (PBPs). PBPs are enzymes involved in the final stages of bacterial cell wall synthesis, and their inhibition leads to cell wall defects, which ultimately result in bacterial lysis and death.

  • Narrow-Spectrum Activity: While many beta-lactam antibiotics affect a broad range of bacteria, Aztreonam specifically targets gram-negative bacteria. Its unique structure allows it to bind selectively to the PBPs found in gram-negative organisms.

  • Resistant to Beta-Lactamase: Aztreonam is relatively resistant to beta-lactamases, enzymes produced by bacteria to degrade beta-lactam antibiotics. This resistance helps Aztreonam maintain its efficacy against many beta-lactamase-producing gram-negative organisms.

Clinical Uses of Aztreonam

Aztreonam is indicated for the treatment of infections caused by aerobic gram-negative bacteria, particularly when these pathogens are resistant to other classes of antibiotics. Below are some of the most common clinical indications for Aztreonam.

1. Respiratory Infections

  • Pneumonia: Aztreonam is used in the treatment of community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP) caused by gram-negative organisms such as Klebsiella pneumoniae, Pseudomonas aeruginosa, and Escherichia coli.

  • Cystic Fibrosis: Aztreonam is frequently used for respiratory tract infections in patients with cystic fibrosis. It is particularly effective in treating Pseudomonas aeruginosa infections in the lungs of these patients. The inhaled form of Aztreonam, marketed as Cayston, is used specifically for these infections.

2. Urinary Tract Infections (UTIs)

Aztreonam is used to treat urinary tract infections (UTIs) caused by Escherichia coli, Klebsiella, and Proteus species. It is an excellent choice for treating complicated UTIs and pyelonephritis when resistant gram-negative organisms are suspected.

3. Abdominal Infections

Aztreonam is effective for treating intra-abdominal infections caused by gram-negative pathogens, particularly in combination with other antibiotics that cover gram-positive organisms and anaerobes. It is commonly used for conditions like peritonitis, cholecystitis, and appendicitis.

4. Sepsis

Aztreonam is often part of combination therapy for patients with sepsis caused by aerobic gram-negative bacteria. In these cases, Aztreonam is used in combination with other antibiotics to cover a broader range of potential pathogens, including gram-positive bacteria and anaerobes.

5. Skin and Soft Tissue Infections

Aztreonam can be used to treat skin and soft tissue infections that are caused by gram-negative bacteria, especially in patients who are allergic to other classes of antibiotics such as penicillins or cephalosporins.

Dosage and Administration

Aztreonam is usually administered by intravenous (IV) or intramuscular (IM) injection, and the dosage depends on the type and severity of the infection, as well as the patient's overall health and renal function. The recommended dosages for common conditions are as follows:

Adult Dosage

  • Respiratory Infections: 1-2 g every 8-12 hours IV or IM.

  • Urinary Tract Infections: 1 g every 8-12 hours IV or IM.

  • Intra-abdominal Infections: 1-2 g every 8-12 hours IV or IM.

  • Sepsis: 2 g every 8 hours IV.

Pediatric Dosage

  • Respiratory Infections in Children: 30-50 mg/kg/day IV or IM, divided into three doses.

  • Urinary Tract Infections in Children: 30-50 mg/kg/day IV or IM, divided into three doses.

  • Intra-abdominal Infections in Children: 30 mg/kg/day IV, divided into three doses.

Side Effects of Aztreonam

While Aztreonam is generally well-tolerated, it can cause a variety of side effects, which range from mild to severe. Below are some of the most common and serious side effects associated with Aztreonam.

Common Side Effects

  • Gastrointestinal Disturbances: Aztreonam can cause nausea, vomiting, and diarrhea. These symptoms are typically mild and transient.

  • Pain at Injection Site: Aztreonam can cause pain, redness, or swelling at the injection site, particularly with IM injections.

  • Rash: Some patients may experience skin rash or mild allergic reactions.

Serious Side Effects

  • Hypersensitivity Reactions: Although rare, Aztreonam can cause severe allergic reactions, including anaphylaxis, angioedema, and severe rash. Immediate medical attention should be sought if signs of an allergic reaction occur.

  • Liver Toxicity: Aztreonam can cause elevations in liver enzymes, such as AST (aspartate aminotransferase) and ALT (alanine aminotransferase), which could indicate liver dysfunction.

  • Clostridium difficile Infection: As with many antibiotics, Aztreonam can disrupt the normal balance of intestinal flora, potentially leading to Clostridium difficile-associated diarrhea (CDAD), a potentially serious condition that can lead to colitis.

  • Severe Diarrhea: If diarrhea becomes severe or persistent, it may indicate antibiotic-associated colitis or C. difficile infection, requiring discontinuation of Aztreonam.

Drug Interactions

Aztreonam may interact with several other drugs, either enhancing its effects or increasing the risk of adverse events. Here are some key drug interactions to be aware of:

Drugs that Increase Aztreonam Levels

  • Probenecid: Probenecid, a medication used to treat gout, can increase the levels of Aztreonam in the bloodstream by inhibiting its renal excretion. This may require dose adjustments in patients on both drugs.

Drugs that May Interact with Aztreonam

  • Other Antibiotics: Aztreonam may interact with other antibiotics that target the cell wall, such as penicillins and cephalosporins, although these interactions are less common and usually managed through careful monitoring.

  • Anticoagulants: Aztreonam may increase the effects of oral anticoagulants like warfarin, which could increase the risk of bleeding. Regular monitoring of INR (International Normalized Ratio) is recommended in patients receiving both Aztreonam and anticoagulants.

Safety Considerations

Pregnancy and Breastfeeding

  • Pregnancy: Aztreonam is classified as Category B by the FDA for pregnancy, meaning that it is generally considered safe when prescribed during pregnancy. However, it should only be used if the benefits outweigh the potential risks.

  • Breastfeeding: Aztreonam is excreted in breast milk in small amounts. Although it is generally considered safe for breastfeeding mothers, it is important to monitor the infant for any potential side effects.

Renal and Hepatic Function

Aztreonam is primarily excreted through the kidneys, so it is important to adjust the dosage in patients with renal insufficiency. Regular monitoring of kidney function is recommended for patients with impaired renal function. In patients with liver disease, Aztreonam should be used with caution, and liver function tests should be monitored regularly.

Conclusion

Aztreonam is a potent monobactam antibiotic that is especially effective against gram-negative bacteria. Its unique spectrum of activity, combined with its ability to resist beta-lactamases, makes it a valuable tool in the treatment of a variety of bacterial infections, particularly in immunocompromised patients and those with cystic fibrosis. Healthcare providers should be mindful of the potential side effects, drug interactions, and safety considerations when prescribing Aztreonam. With appropriate monitoring and dosing adjustments, Aztreonam can effectively treat infections caused by resistant gram-negative pathogens and contribute to the ongoing fight against antibiotic resistance.